Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are neutral on ABT stock.
Abbott Laboratories (ABT) Stock: More Robust Than the Numbers Suggest?
On Wednesday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.82 which represents a slight increase of $1.77 or 1.53% from the prior close of $116.05. The stock opened at $118.
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was approved by Abbott’s board of directors this month, the North Chicago-based company announced today in conjunction with revealing its third-quarter earnings.
Abbott Laboratories (ABT) Gets a Buy from Piper Sandler
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a
Abbott Laboratories 3Q Sales Top Expectations
Abbott Laboratories posted better-than-expected sales in its latest quarter, which it attributed to strong underlying base business performance. The healthcare-products manufacturer logged earnings of $1.
Why Abbott Laboratories Stock Was a Winner on Wednesday
Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up by 1.
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Laboratories Raises Its Outlook on Strong Medical Device Sales
Key Takeaways Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical ...
Abbott Laboratories: Strong Buy Rating Driven by Robust Growth Prospects and Operational Improvements
Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...
Abbott bumps up profit forecast on strong medical device sales
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...
Travis Steed Reiterates Buy Rating on Abbott Laboratories Amid Promising Growth and Under-Ownership Potential
Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The ...
Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...